MARKET

APLT

APLT

Applied Therapeutics
NASDAQ
0.3330
+0.0292
+9.61%
After Hours: 0.3401 +0.0071 +2.13% 19:16 04/17 EDT
OPEN
0.3121
PREV CLOSE
0.3038
HIGH
0.3463
LOW
0.3121
VOLUME
1.78M
TURNOVER
--
52 WEEK HIGH
10.62
52 WEEK LOW
0.2950
MARKET CAP
47.14M
P/E (TTM)
-0.4399
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Applied Therapeutics (APLT)
TipRanks · 1d ago
Applied Therapeutics Reports 2024 Financial Results and Leadership Changes
TipRanks · 2d ago
APPLIED THERAPEUTICS, INC. 2024 FORM 10-K ANNUAL REPORT
Press release · 3d ago
Applied Therapeutics (APLT) Gets a Hold from RBC Capital
TipRanks · 3d ago
William Blair Sticks to Its Hold Rating for Applied Therapeutics (APLT)
TipRanks · 3d ago
Applied Therapeutics FY 2024 GAAP EPS $(0.76) Beats $(1.37) Estimate
Benzinga · 3d ago
Applied Therapeutics reports FY24 EPS (76c), consensus ($1.33)
TipRanks · 4d ago
*Applied Therapeutics 2024 Rev $455,000 >APLT
Dow Jones · 4d ago
More
About APLT
More
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Recently
Symbol
Price
%Change

Webull offers Applied Therapeutics Inc stock information, including NASDAQ: APLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLT stock methods without spending real money on the virtual paper trading platform.